2022 - Major CGMP Issues - US FDA Concerns in 2022

Areas Covered in the Webinar:
Recent industry trends, bad and good
The FDA’s Strategic Priorities
Major foreseeable problem areas for 2022 onward - The "Heavy Hitters"
A company gap analysis
Correcting problem-prone areas
Avoid complacency from past “good” audits
The Most Frequent / Serious 483’s – 483’s that generate Warning Letters
The risk-based phased approach – what does that mean
Prove “State of Control”
Entropy - a major "player"